Clinical trials: Attention Deficits
Attention Deficit Hyperactivity Disorder
Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR
The purpose of this study is to evaluate how children and adolescents with Attention Deficit/ Hyperactivity Disorder (ADHD) respond to treatment with three differing doses of stimulant medications used to treat ADHD, Adderall XR®…
- Trial name
- NCT00393042
- Testing
- Dexmethylphenidate, Mixed Amphetamine Salts, ER
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Seattle Children's Hospital
Conduct Disorder
Trial of Aripiprazole in the Treatment of CD in Adolescents
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.
- Trial name
- NCT00250705
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Attention Deficit Hyperactivity Disorder
Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children
This is a pilot study evaluating the effectiveness, safety, and tolerability of Ritalin LA in treating Attention Deficit Hyperactivity Disorder (ADHD) in 4 and 5 year old children.
- Trial name
- NCT00754208
- Testing
- methylphenidate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT01439126
- Testing
- clonidine hydrochloride
- Volunteers
- 135 people
- Sponsor
- Concordia Pharmaceuticals Inc., Barbados
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit Hyperactivity Disorder
Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study
The primary goal of the project is to test personalized medication experiments to inform decisions about future medication use. Our central hypothesis is that our intervention will lead to within subject increases in adolescent…
- Trial name
- NCT06305078
- Testing
- Personalized ADHD Medication Experiment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Conduct Disorder, Oppositional Defiant Disorder
School-Based Mental Health Services for Urban Children
This study will evaluate the effectiveness of school- and home-based mental health services and training modules in supporting learning and behavior in financially disadvantaged children who live in urban areas.
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Attention Deficit Disorder With Hyperactivity
- Trial name
- NCT00612690
- Testing
- Community mental health consultation model program, Treatment as usual (TAU)
- Where
- United States
- Volunteers
- 482 people
- Sponsor
- University of Illinois Chicago
ADHD
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
- Trial name
- NCT00764868
- Testing
- Lisdexamfetamine Dimesylate (LDX)
- Where
- 45 sites in United States
- Volunteers
- 269 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
- Trial name
- NCT02083783
- Testing
- TRI102
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Tris Pharma, Inc.
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders
The objective of this K01 study was to pilot a sequential, multiple assignment, randomized trial (SMART) design to compare the impact of a sequence of sleep interventions, based on participant treatment response, to optimize…
- Conditions
- Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Sleep Disturbance
- Trial name
- NCT03730194
- Testing
- Melatonin, Bedtime Bank
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
LYDO is a multi-center study that will enroll approximately 1925 adult outpatients with Attention Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00700427
- Testing
- atomoxetine hydrochloride
- Where
- 56 sites in Austria, Belgium and 10 more
- Volunteers
- 2,017 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
- Trial name
- NCT02777931
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Autism, Attention Deficit Disorder With Hyperactivity
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD.
- Trial name
- NCT00178503
- Testing
- Methylphenidate-extended release, Methylphenidate-immediate release
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Sleep Apnea, Obstructive, Sleep Apnea Syndromes
Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children
Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood.
- Conditions
- Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity
- Trial name
- NCT01554527
- Testing
- CPAP treatment, No CPAP treatment
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Michigan
Attention-Deficit/Hyperactivity Disorder
Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
This proposal seeks to obtain preliminary data on the potential efficacy, tolerability, and feasibility of trigeminal nerve stimulation (TNS) as a treatment for Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01388530
- Testing
- EMS 7500 Digital Muscle Stimulator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom…
- Trial name
- NCT03649074
- Testing
- AKL-T01
- Where
- 2 sites in United States
- Volunteers
- 206 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Disorder With Hyperactivity
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
This study will determine the effectiveness of stimulant and nonstimulant medication in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
- Trial name
- NCT00183391
- Testing
- Atomoxetine, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 232 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company